Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 1/2 Completed 18 enrolled aTyr Pharma, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.

Evaluation	Drug	Modality	Dose	Route
Subject	ATYR1940	Unknown	0.3 mg/kg	Intravenous
Subject	ATYR1940	Unknown	1 mg/kg	Intravenous
Subject	ATYR1940	Unknown	3 mg/kg	Intravenous